Risk stratification for thrombosis in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
| . | Essential Thrombocythemia . | Polycythemia Vera . |
|---|---|---|
| * The role of familial thrombophilia or cardiovascular disease in risk stratification is controversial. | ||
| ** An intermediate risk catergory particularly for PV is controversial | ||
| Low risk: | Patients aged less than 40 years with all of the following: NO prior thrombosis or hemorrhage NO hypertension or diabetes Platelet count < 1500 x 109/L NO familial thrombophilia/cardiovascular disease* | Patients aged less than 40 years with all of the following: NO prior thrombosis or hemorrhage NO congestive cardiac failure, hypertension or diabetes NO familial thrombophilia/cardiovascular disease* NO symptomatic or progressive splenomegaly |
| Intermediate risk: | **Patients aged 40–60 years with all of the following: NO prior thrombosis NO hypertension or diabetes Platelet count < 1500 x 109/L OR Patients aged < 60 years and: familial thrombophilia/cardiovascular disease* | Patients aged 40–60 years with all of the following NO prior thrombosis NO congestive cardiac failure, hypertension or diabetes Platelet count < 1500 x 109/L NO progressive or symptomatic splenomegaly OR Patients aged < 60 years and: familial thrombophilia/cardiovascular disease* |
| High risk: | Patients either age > 60 years, or with any one of the following: Prior thrombosis or hemorrhage Platelet count > 1000 – 1500 x 109/) Hypertension Diabetes requiring treatment | Patients either age > 60 years, or with any one of the following: Prior thrombosis or hemorrhage Platelet count > 1000–1500 x 109/L) Congestive cardiac failure Hypertension Diabetes Progressive or symptomatic splenomegaly |
| . | Essential Thrombocythemia . | Polycythemia Vera . |
|---|---|---|
| * The role of familial thrombophilia or cardiovascular disease in risk stratification is controversial. | ||
| ** An intermediate risk catergory particularly for PV is controversial | ||
| Low risk: | Patients aged less than 40 years with all of the following: NO prior thrombosis or hemorrhage NO hypertension or diabetes Platelet count < 1500 x 109/L NO familial thrombophilia/cardiovascular disease* | Patients aged less than 40 years with all of the following: NO prior thrombosis or hemorrhage NO congestive cardiac failure, hypertension or diabetes NO familial thrombophilia/cardiovascular disease* NO symptomatic or progressive splenomegaly |
| Intermediate risk: | **Patients aged 40–60 years with all of the following: NO prior thrombosis NO hypertension or diabetes Platelet count < 1500 x 109/L OR Patients aged < 60 years and: familial thrombophilia/cardiovascular disease* | Patients aged 40–60 years with all of the following NO prior thrombosis NO congestive cardiac failure, hypertension or diabetes Platelet count < 1500 x 109/L NO progressive or symptomatic splenomegaly OR Patients aged < 60 years and: familial thrombophilia/cardiovascular disease* |
| High risk: | Patients either age > 60 years, or with any one of the following: Prior thrombosis or hemorrhage Platelet count > 1000 – 1500 x 109/) Hypertension Diabetes requiring treatment | Patients either age > 60 years, or with any one of the following: Prior thrombosis or hemorrhage Platelet count > 1000–1500 x 109/L) Congestive cardiac failure Hypertension Diabetes Progressive or symptomatic splenomegaly |